Optical imaging biomarker to predict lung disease outcomes in IPF
Official title: Optical imaging biomarker to predict disease outcomes in pulmonary fibrosis
Funded at Massachusetts General Hospital · NIH-11374250 · Data updated 2026-11-12
A new imaging test using tiny endobronchial optics could help predict how IPF will progress and who might need a transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 15, 2026 |
| Project end | March 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,664,696 |
| NIH project number | 1R01HL181336-01A1 |
| Project ID | NIH-11374250 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults recently diagnosed with idiopathic pulmonary fibrosis who are undergoing endobronchial procedures and consent to advanced lung imaging.
✕Less likely to help
Patients unable to undergo the required endobronchial PS-OCT imaging or who do not have IPF may not benefit.
What this research studies
This project aims to create a patient-specific optical biomarker from a minimally invasive endobronchial PS-OCT scan taken at diagnosis to forecast disease progression and risk of death in idiopathic pulmonary fibrosis. By capturing microscopic activity of fibrogenesis, the test intends to improve timing of treatments and referrals, including potential transplant consideration. The study leverages high-resolution 3D lung imaging to look for patterns that traditional tests miss, across various regions of the lungs. The goal is to give clinicians a more accurate and timely picture of prognosis to guide care decisions.
Why it matters
Potential benefit: If successful, patients and clinicians could plan more effectively, potentially improving survival and quality of life through earlier, better-informed decisions.
How similar studies have gone: High-resolution optical imaging has shown promise in other lung diseases, but this approach is novel for IPF prognosis.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Hariri, Lida P — Massachusetts General Hospital
- Study coordinator: Hariri, Lida P
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.